The most telling comparison is the market cap of ALA - Arovella
I don’t understand the tech well enough to see the differences but they are at similar levels of cash flow and probably behind CHM on drug development, and they’re valuable at 100m+
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment, page-12
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.07M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.8¢ | 1.6¢ | $25.89K | 1.531M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1823364 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 239298 | 1 |
View Market Depth
| Last trade - 12.36pm 28/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |